Streetbeat News

CTCX

Carmell Therapeutics Corporation

https://www.carmellrx.com

Industry

Biotechnology

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Carmell shares are trading higher after the company appointed Kendra Bracken-Ferguson as CEO.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 4:50 pm

Carmell Corporation (NASDAQ:CTCX) has appointed Kendra Bracken-Ferguson as CEO, effective July 30, 2024. Rajiv Shukla will continue as Executive Chairman. The company has made significant strides since its business combination in July 2023, including product development, scaling manufacturing, and reducing cash burn.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:40 pm

Carmell Therapeutics has filed with the SEC for the resale of up to 1.3 million common shares by the selling stockholders. This move indicates a potential increase in the company's public float, which could have various impacts on its stock price.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:31 pm

Nucor Corporation's shares fell after reporting lower-than-expected quarterly results. Other stocks showed significant movement, with Cyngn Inc. and Pineapple Energy Inc. among the top gainers, while Abeona Therapeutics and Greenwave Technology Solutions were notable losers.

Portfolio Pulse from Avi Kapoor

April 23, 2024 | 5:53 pm

Carmell Therapeutics (CTCX) announced a $3 million private placement of approximately 1,333,333 shares of its common stock at a price of $2.25 per share, leading to a decrease in its stock price.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 5:00 pm

Health care stocks experienced significant movements in Thursday's intraday session. Candel Therapeutics, TC BioPharm, Eiger BioPharmaceuticals, Macrogenics, Barinthus Biotherapeutics, and Curis saw notable gains, with increases ranging from 24.62% to 64.3%. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, Inotiv, Universe Pharmaceuticals, Kintara Therapeutics, and Carmell faced declines, with decreases ranging from 12.85% to 80.2%. The movements were attributed to various factors, including earnings releases and market dynamics.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:31 pm

Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company, announced a private placement of approximately 1,333,333 shares at $2.25 each, totaling $3M in gross proceeds. The CEO participated at $2.88 per share, the closing price on April 3, 2024. Post-placement, Carmell will have about 20.58 million shares outstanding. Brookline Capital Markets was the exclusive placement agent.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:57 pm

Carmell Therapeutics (CTCX) has announced the sale of its Axolotl Biologix subsidiary. The transaction includes 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock, and notes payable to the initial sellers totaling $8 million.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 8:40 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Notably, Better Therapeutics (BTTX) surged by 65.4%, while SELLAS Life Sciences Gr (SLS) dropped by 28.7%. Other notable gainers include Carmell (CTCX) and P3 Health Partners (PIII), with increases of 38.52% and 38.23% respectively. On the losing end, Immuneering (IMRX) and Lucy Scientific Discovery (LSDI) saw declines of 28.45% and 25.64%. These movements reflect the volatile nature of healthcare stocks in the market.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 5:31 pm

Freshpet, Inc. (NASDAQ:FRPT) shares surged 15.5% after reporting Q4 earnings and sales above estimates. Other stocks also moved significantly in Monday's mid-day session, with notable gainers including Akili, Inc. (NASDAQ:AKLI), ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), and MicroCloud Hologram Inc. (NASDAQ:HOLO), among others. Losers included Aclarion, Inc. (NASDAQ:ACON) and Venus Concept Inc. (NASDAQ:VERO).

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 6:57 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.